Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Arrowhead Pharmaceuticals

Explore full profile

Gene silencing platform targeting liver, lung, CNS, and metabolic diseases

Pasadena, United StatesFounded 2003Biotech & Life Sciences
Valuation $11B Market cap · Aug/2026
Revenue $442M Latest reported FY

At a glance

Status
Listed
Founded
2003
Headquarters
Pasadena, United States
Listing
Public via SPAC 2004
Sector
Biotech & Life Sciences
Power Law
Decacorn$10B+ valuation tierThoroughbred$100M+ revenue

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom
News
News Arrowhead's ARO-MAPT cuts brain tau by 73% in early trial, a first for RNAi delivery to the brain Oct 16, 2026 News Arrowhead's first dual-target RNAi drug slashes both cholesterol and triglycerides in early trial Sep 16, 2026 News Arrowhead's plozasiran hits primary endpoint in Phase 3 SHASTA-3 and SHASTA-4 Jul 22, 2026

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later4 investors entered at this stage

Talent

Book a demo to see the people
Employees mapped 746 incl. 1 AI specialist
Founders Hidden — book a demo/100 quality score
Key operators 28 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Pasadena HQ
Book a demo for the full country breakdown
Web traffic by country
43K monthly visits
across markets
🇺🇸 United States74.2%
🇬🇧 United Kingdom4%
🇳🇬 Nigeria3.5%
🇮🇳 India3.3%
🏳️ Korea3%
Top 5 markets shown

Patents

Estimated portfolio value
$200M

130 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Investments and acquisitions

Disclosed deals where Arrowhead Pharmaceuticals was the backer or acquirer, 2006–2022. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across Arrowhead Pharmaceuticals's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        Arrowhead Pharmaceuticals's portfolio, mapped.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        Posts on X, past 7 days

        An AI-synthesised read of the highest-engagement posts about Arrowhead Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Arrowhead Pharmaceuticals on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles